Information Notice No. 85-61, Supplement 1: Misadministrations to Thyroid Scans
SSINS No: 6835
IN 85-61
Supplement No. 1
UNITED STATES
NUCLEAR REGULATORY COMMISSION
OFFICE OF INSPECTION AND ENFORCEMENT
WASHINGTON, D.C. 20555
April 15, 1987
Information Notice No. 85-61, SUPPLEMENT 1: MISADMINISTRATIONS TO
PATIENTS UNDERGOING
THYROID SCANS
Addressees:
All licensees authorized to use byproduct material for human applications.
This notice supplements Information Notice No. 85-61 (attached). It is
expected that licensees will review this supplemental information for
applicability to their activities and consider actions, if appropriate, to
preclude further iodine-131 misadministrations. However, suggestions
contained in this information notice do not constitute NRC requirements;
therefore, no specific actions or written response is required.
Description of Circumstances:
Since the original notice was issued on July 22, 1985, the NRC has reviewed
14 additional iodine-131 misadministrations. The probable causes of these
misadministrations are as follows:
o The cause of 8 of the 14 misadministrations can be ascribed to the
referring physician's order being misinterpreted or to a
miscommunication to the technologists.
o The cause of three other misadministrations can be ascribed to the
technologists not being sufficiently familiar with the iodine-131
dosage requirements for thyroid scan procedures that involve scanning
the chest area to ensure that the proper dosage was used.
o The cause of the remaining three misadministrations can be ascribed to
miscellaneous factors: a patient's identity was not verified before
administering the iodine-131 dosage; the technologist selected the
wrong iodine-131 capsule from the isotope laboratory and did not assay
it to ensure proper dosage before administering it to the patient; and
the nuclear medicine physician or radiologist was not aware that part
of the patient's thyroid was intact before prescribing the amount of
iodine-131 for administration to the patient for a whole-body
iodine-131 scan.
8704090053
.
IN 85-61 Supplement No. 1
April 15, 1987
Page 2 of 3
Discussion:
Licensees that have experienced such misadministrations have found that the
following corrective actions have been effective tn preventing iodine-131
misadministrations.
o Provide periodic refresher training for nuclear medicine personnel
involved in the performance of thyroid studies that emphasizes the
effects on patients resulting from misadministrations involving
iodine-131. Maintain records of such training.
o For licensees conducting infrequent or nonroutine nuclear medicine
procedures involving the administration of iodine-131, ensure that the
authorized user, and any physicians under the supervision of the
authorized user, as well as the technologists involved are sufficiently
familiar with these procedures so that they will be properly conducted.
o Establish a manual that contains the groper procedures for each of the
nuclear medicine studies (i.e., thyroid uptake, thyroid uptake and
scan, thyroid neck and chest, thyroid whole-body scan, etc.).
o Ensure that all thyroid studies referred to the nuclear medicine
department involving the administration of iodine-131 will be in
written form and the authorized user, or any physicians under the
supervision of the authorized user, will prescribe an appropriate
thyroid study for the particular patient conditions. For example,
interview the patient, obtain additional information from the referring
physician if needed, examine the patient, and sign the iodine-131
thyroid study prescription.
o Instruct all personnel involved in the performance of iodine-131
studies to request clarification from the prescribing physician if any
element of a prescription or procedure is unclear, ambiguous, or
apparently erroneous.
o Before each administration to a patient (adult or child), always
calculate the required dosage for the prescribe procedure, and then
ensure the correct dosage is prepared by calibrating that dose in the
dose calibrator.
o Ensure compliance with 10 CFR 35.53, measurement of radiopharmaceutical
dosages, 35.60, syringe shields and labels, and 35.61, vial shields and
labels prior to administration of iodine-131, and maintain records of
dosage disposition.
.
IN 85-61 Supplement No. 1
April 15, 1987
Page 3 of 3
No specific written response is required by this information notice. If you
have any questions regarding this matter, please contact the Regional
Administrator of the appropriate NRC regional office or this office.
Edward L. Jordan Director
Division of Emergency Preparedness
and Engineering Response
Office of Inspection and Enforcement
Technical Contact: H. Karagiannis, IE
(301) 427-9030
Attachments:
1. Information Notice No. 85-61
2. List of Recently Issued IE Information Notices
Page Last Reviewed/Updated Tuesday, March 09, 2021